Clovis Oncology, Inc. was a big mover last session, as the company saw its shares rise over 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 73.2% in the past one-month time frame.

The move came after the company announced  the pricing of an underwritten public offering of 3.4 million shares of its common stock at $88.00 per share.

The company has seen three positive estimate revisions in the past few months versus one revision in the opposite direction. As a result, its Zacks Consensus Estimate for the current quarter has also improved over the past two months, suggesting that more solid trading could be ahead for Clovis Oncology. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

Clovis Oncology currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Clovis Oncology, Inc. Price and Consensus

Investors interested in the Medical - Biomedical and Geneticsindustry may consider a better-ranked stock like VIVUS, Inc. VVUS, which carries a Zacks Rank #1 (Strong Buy).

Is CLVS going up? Or down? Predict to see what others think: Up or Down

Looking for Ideas with Even Greater Upside?

Most of Zacks’ investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more. Click here for a peek at this private information>>